TBC1D7

Across TCGA pan-cancer cohorts, TBC1D7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TBC1D7 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TBC1D7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D7 expression acts as an unfavorable survival marker.

LUSC, KICH, and SKCM are the cancer types where TBC1D7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.126	0.664	.008	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TBC1D7–LUSC (OS)

Open the LUSC breakdown →